Anti-Human HLA-DP (MHC Class II) Monomorphic [Clone B7/21] — Purified in vivo GOLD™ Functional Grade
Anti-Human HLA-DP (MHC Class II) Monomorphic [Clone B7/21] — Purified in vivo GOLD™ Functional Grade
Product No.: H260
Clone B7/21 Target HLA-DP Monomorphic Formats AvailableView All Product Type Monoclonal Antibody Alternate Names HLA-DP Monomorphic, HLADP, HLA-DPαβ, DPA and DPB, DPα and DPβ, DPαβ Isotype Mouse IgG3 Applications FC , ICC |
Antibody DetailsProduct DetailsReactive Species Human Host Species Mouse Recommended Isotype Controls Mouse IgG3 Recommended Dilution Buffer Immunogen Unknown Product Concentration ≥ 5.0 mg/ml Endotoxin Level < 1.0 EU/mg as determined by the LAL method Purity ≥95% monomer by analytical SEC ⋅ >95% by SDS Page Formulation This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added. Due to inherent biochemical properties of antibodies, certain products may be prone to precipitation over time. Precipitation may be removed by aseptic centrifugation and/or filtration. Product Preparation Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates. Storage and Handling Functional grade preclinical antibodies may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles. Country of Origin USA Shipping Next Day 2-8°C RRIDAB_2737518 Applications and Recommended Usage? Quality Tested by Leinco FC Additional Applications Reported In Literature ? ICC Each investigator should determine their own optimal working dilution for specific applications. See directions on lot specific datasheets, as information may periodically change. DescriptionDescriptionSpecificity Clone B7/21 recognizes a monomorphic epitope on human HLA-DP1, -DP2, -DP3, -DP4, and -DP5. It does not cross-react with HLA-DR or HLA-DQ.
Background HLA-DP antibody, clone B7/21, recognizes the major histocompatibility complex (MHC) class II molecule Human Leukocyte Antigen - DP isotype (HLA-DP). MHC class II is constitutively expressed on human professional antigen-presenting cells (APCs), including macrophages/monocytes, dendritic cells (DCs), and B cells, and is induced on T cells upon activation1. HLA-DP consists of two transmembrane proteins, a 35 kDa α (heavy) chain and 29 kDa β (light) chain2 encoded by the HLA-DPA1 and HLA-DPB1 genes, respectively, located in the HLA complex of chromosome 6. The N-terminal α1 and β1 domains form the antigen-binding groove, which binds 13-25 aa peptides derived from exogenous antigens3. On APCs, MHC class II plays a critical role in the adaptive immune response by presenting phagocytosed antigens to helper CD4 T cells. The T cell receptor (TCR)/CD3 complex of CD4 T cells interacts with peptide-MHC class II, which induces CD4 T cell activation leading to the coordination and regulation of other effector cells. CD4 molecules also bind to MHC class II, which helps augment TCR signaling4. It has also been demonstrated that MHC class II express on activated T cells are capable of antigen presentation5 and can transduce signals into T cells, enhancing T cell proliferation and activity6. High HLA-DP expression is associated with an increased risk of graft-versus-host disease7. Specific alleles of HLA-DP are associated with autoimmune diseases, including rheumatoid arthritis8. Antigen Distribution HLA-DP is expressed on antigen-presenting cells, including macrophages, monocytes, DCs, and B cells, and activated T cells.
PubMed Research Area Immunology . Innate Immunity Leinco Antibody AdvisorPowered by AI: AI is experimental and still learning how to provide the best assistance. It may occasionally generate incorrect or incomplete responses. Please do not rely solely on its recommendations when making purchasing decisions or designing experiments. Clone B7/21 is a monoclonal antibody that specifically recognizes a monomorphic epitope on human HLA-DP molecules, predominantly used in flow cytometry and related applications to analyze human cells. There is no evidence in the provided search results that B7/21 is used directly for in vivo mouse studies. Key context and application details:
Summary Table: Specificity and In Vivo Use of B7/21
If your aim is to study MHC class II molecules in murine models, you should use antibodies specific to mouse MHC II (e.g., anti-I-A, anti-I-E clones). Clone B7/21 is not appropriate for direct immunological studies in mice unless the mice contain human cells expressing HLA-DP. Commonly used antibodies or proteins paired with B7/21 (which targets HLA-DP, a human MHC Class II antigen) in the literature often include other MHC Class II antibodies and markers for immune cell characterization. The most frequent combinations are:
The exact combination depends on the experimental or clinical contextsuch as flow cytometry panels, immunohistochemistry, or functional immune assays. The use of switch-variant B7/21 (IgG1 vs. IgG3) is another detail sometimes explored for blocking or cross-blocking experiments in studies of HLA-DP specificity. In summary, anti-HLA-DR, anti-HLA-DQ, immue cell-type markers (CD4, CD8, CD14, CD19), and various co-signaling molecule antibodies (PD-L1, B7-H3, CD25, CTLA-4) are most commonly used in conjunction with B7/21 in the literature. Clone B7/21 is a well-established monoclonal antibody that specifically recognizes a monomorphic epitope on human HLA-DP and is widely used in immunological studies to identify or block HLA-DP molecules. Key findings from scientific literature citing clone B7/21 include:
There is no evidence in these results that clone B7/21 is associated with functional signaling upon binding (i.e., it does not appear to modulate HLA-DP function, but serves rather as a blocking or detection reagent). Accordingly, the key scientific contributions of clone B7/21 are its robust specificity for HLA-DP and its broad experimental utility in immunology for distinguishing or functionally interrogating HLA-DP in both basic and translational research. Dosing regimens for clone B7/21, a monoclonal antibody targeting human HLA-DP antigens, are not specifically outlined for in vivo mouse studies in publicly available dosing guides or experimental reports. The details available primarily describe its specificity and applications (e.g., immunocytochemistry on human cells), but do not provide mouse dosing schedules, routes, or variations across different mouse models. Essential context:
Additional relevant information:
In summary, there are no standardized or published dosing regimens for B7/21 across mouse models. Its use is limited to assays with human cells, and any adaptation for in vivo mouse studies (such as humanized mice) would require case-specific pilot dosing. References & Citations1. Holling TM, et al. (2004) Hum Immunol. 65(4):282-90. 2. Mitaksov V & Fremont DH. (2006) J Biol Chem. 281(15):10618-25. 3. Wieczorek M, et al. (2017) Front Immunol. 8:292. 4. Artyomov MN, et al. (2010) Proc Natl Acad Sci USA. 107(39):16916-16921. 5. Barnaba V, et al. (1994) Eur J Immunol. 24(1):71-5. 6. Di Rosa F, et al. (1993) Hum Immunol. 38(4):251-60. 7. Petersdorf EW, et al. (2015) N Engl J Med. 373(7):599-609. 8. Raychaudhuri S, et al. (2012) Nat Genet. 44(3):291-6. Technical ProtocolsCertificate of Analysis |
Related Products
Prod No. | Description |
---|---|
H261 | |
H262 | |
H263 | |
H1685 |
Formats Available
Prod No. | Description |
---|---|
H266 | |
H260 | |
H252 | |
H254 | |
H250 | |
H127 |
